Literature DB >> 30855374

Trimodality therapy for bladder cancer: modern management and future directions.

Anthony Pham1, Leslie K Ballas.   

Abstract

PURPOSE OF REVIEW: This review examines both trimodality therapy (TMT) in the definitive management of bladder cancer as well as the use of adjuvant radiotherapy for bladder cancer with a specific focus on publications from the last 2 years. RECENT
FINDINGS: TMT is an effective management strategy for muscle invasive bladder cancer with outcomes similar to radical cystectomy. Effectiveness of this strategy exists in variant histologies and can be personalized with use of biomarkers. There is a role for adjuvant radiotherapy in locally advanced bladder cancer, especially in the age of improved imaging and modern radiotherapy techniques.
SUMMARY: This review should provide the reader data necessary to support use of TMT and adjuvant radiation therapy in their clinic.

Entities:  

Mesh:

Year:  2019        PMID: 30855374      PMCID: PMC7440298          DOI: 10.1097/MOU.0000000000000601

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  42 in total

1.  Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy.

Authors:  Ross E Krasnow; Michael Drumm; Hannah J Roberts; Andrzej Niemierko; Chin-Lee Wu; Shulin Wu; Jing Zhang; Niall M Heney; Matthew F Wszolek; Michael L Blute; Adam S Feldman; Richard J Lee; Anthony L Zietman; William U Shipley; Jason A Efstathiou
Journal:  Eur Urol       Date:  2016-12-28       Impact factor: 20.096

2.  Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial.

Authors:  Mohamed S Zaghloul; John P Christodouleas; Andrew Smith; Ahmed Abdallah; Hany William; Hussein M Khaled; Wei-Ting Hwang; Brian C Baumann
Journal:  JAMA Surg       Date:  2018-01-17       Impact factor: 14.766

3.  Risk stratification for locoregional recurrence after radical cystectomy for urothelial carcinoma of the bladder.

Authors:  Vladimir Novotny; Michael Froehner; Matthias May; Chris Protzel; Katrin Hergenröther; Michael Rink; Felix K Chun; Margit Fisch; Florian Roghmann; Rein-Jüri Palisaar; Joachim Noldus; Michael Gierth; Hans-Martin Fritsche; Maximilian Burger; Danijel Sikic; Bastian Keck; Bernd Wullich; Philipp Nuhn; Alexander Buchner; Christian G Stief; Stefan Vallo; Georg Bartsch; Axel Haferkamp; Patrick J Bastian; Oliver W Hakenberg; Stefan Propping; Atiqullah Aziz
Journal:  World J Urol       Date:  2015-02-08       Impact factor: 4.226

4.  Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy.

Authors:  Mark C Korpics; Alec M Block; Brendan Martin; Courtney Hentz; Ellen R Gaynor; Elizabeth Henry; Matthew M Harkenrider; Abhishek A Solanki
Journal:  Cancer       Date:  2017-06-05       Impact factor: 6.860

5.  Tolerance of Orthotopic Ileal Neobladders to Radiotherapy: A Multi-institutional Retrospective Study.

Authors:  Leslie Ballas; Paul Sargos; Mathieu Orré; Shelly X Bian; Siamak Daneshmand; Libni J Eapen
Journal:  Clin Genitourin Cancer       Date:  2017-05-10       Impact factor: 2.872

6.  The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response.

Authors:  D S Kaufman; K A Winter; W U Shipley; N M Heney; M P Chetner; L Souhami; R A Zlotecki; W T Sause; L D True
Journal:  Oncologist       Date:  2000

7.  Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer.

Authors:  David B Cahn; Elizabeth A Handorf; Eric M Ghiraldi; Benjamin T Ristau; Daniel M Geynisman; Thomas M Churilla; Eric M Horwitz; Mark L Sobczak; David Y T Chen; Rosalia Viterbo; Richard E Greenberg; Alexander Kutikov; Robert G Uzzo; Marc C Smaldone
Journal:  Cancer       Date:  2017-07-25       Impact factor: 6.860

8.  Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.

Authors:  Donald S Kaufman; Kathryn A Winter; William U Shipley; Niall M Heney; H James Wallace; Leonard M Toonkel; Anthony L Zietman; Simon Tanguay; Howard M Sandler
Journal:  Urology       Date:  2008-12-18       Impact factor: 2.649

9.  Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.

Authors:  Timur Mitin; Asha George; Anthony L Zietman; Niall M Heney; Donald S Kaufman; Robert G Uzzo; Robert Dreicer; H James Wallace; Luis Souhami; M Chris Dobelbower; Howard M Sandler; William U Shipley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-09-28       Impact factor: 7.038

10.  First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.

Authors:  Arjun V Balar; Daniel Castellano; Peter H O'Donnell; Petros Grivas; Jacqueline Vuky; Thomas Powles; Elizabeth R Plimack; Noah M Hahn; Ronald de Wit; Lei Pang; Mary J Savage; Rodolfo F Perini; Stephen M Keefe; Dean Bajorin; Joaquim Bellmunt
Journal:  Lancet Oncol       Date:  2017-09-26       Impact factor: 41.316

View more
  16 in total

1.  A global, regional, and national survey on burden and Quality of Care Index (QCI) of bladder cancer: The global burden of disease study 1990-2019.

Authors:  Amirali Karimi; Parnian Shobeiri; Sina Azadnajafabad; Masoud Masinaei; Negar Rezaei; Ali Ghanbari; Nazila Rezaei; Mahtab Rouhifard; Sarvenaz Shahin; Mohammad-Mahdi Rashidi; Mohammad Keykhaei; Ameneh Kazemi; Erfan Amini; Bagher Larijani; Farshad Farzadfar
Journal:  PLoS One       Date:  2022-10-20       Impact factor: 3.752

2.  Hsa_circRNA_100146 Acts as a Sponge of miR-149-5p in Promoting Bladder Cancer Progression via Regulating RNF2.

Authors:  Hengbing Wang; Xiaobing Niu; Fei Mao; Xuzhong Liu; Bing Zhong; Hesong Jiang; Guangbo Fu
Journal:  Onco Targets Ther       Date:  2020-10-29       Impact factor: 4.147

3.  Conditional survival of trimodal therapy for nonmetastatic muscle-invasive bladder cancer: A SEER database analysis.

Authors:  Wentai Shangguan; Jintao Hu; Yingwei Xie; Zhiliang Chen; Qiyu Zhong; Zaosong Zheng; Dingjun Zhu; Yishan Zhang; Jingying Yang; Jinli Han; Wenlian Xie
Journal:  Cancer Med       Date:  2022-03-18       Impact factor: 4.711

4.  Bladder preservation versus radical cystectomy in transitional cell carcinoma and squamous cell carcinoma muscle invasive bladder cancer.

Authors:  Dalia O Mohamed; Mona M Sayed; Islam F Abdelkawi; Mahmoud H Elshoieby; Salah M Khallaf; Lamia M Khallaf; Doaa M Fouad
Journal:  Curr Urol       Date:  2021-03-29

5.  The Application Effect of Traditional Chinese Medicine Nursing on General Anesthesia Combined with Epidural Anesthesia and Electric Resection for the Treatment of Bladder Cancer and Its Influence on Tumor Markers.

Authors:  Yan Wu; Zhenna Zhang; Yangfan Liu; Guangwen Shi; Xuehai Ding
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-15       Impact factor: 2.629

6.  Systematic review and meta-analysis on laparoscopic cystectomy in bladder cancer.

Authors:  Jialiang Zhu; Ziwen Lu; Wanbo Chen; Mang Ke; Xianguo Cai
Journal:  Transl Androl Urol       Date:  2022-01

Review 7.  [Locally advanced or oligometastatic bladder cancer-role of local treatment of the primary tumor and metastases].

Authors:  Katharina Rebhan; Kilian M Gust
Journal:  Urologe A       Date:  2021-11-26       Impact factor: 0.639

8.  Three-Dimensional Ultrasound Images in the Assessment of Bladder Tumor Health Monitoring under Deep Learning Algorithms.

Authors:  Changhua Shao; Aichun Sun; Hanwen Xue; Xianqiang Di
Journal:  Comput Math Methods Med       Date:  2022-03-23       Impact factor: 2.238

9.  Preoperative Nutritional Risk Assessment for Predicting Complications after Radical Cystectomy plus Urinary Diversion for Bladder Cancer.

Authors:  Xing Wei; Jia Wang; Haitao Liu; Weizhe Fan; Gang Guo
Journal:  Emerg Med Int       Date:  2022-08-16       Impact factor: 1.621

10.  Global, regional, and national burdens of bladder cancer in 2017: estimates from the 2017 global burden of disease study.

Authors:  Hairong He; Hongjun Xie; Yule Chen; Chengzhuo Li; Didi Han; Fengshuo Xu; Jun Lyu
Journal:  BMC Public Health       Date:  2020-11-11       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.